Phase I-II trial of weekly bicalutamide in men with elevated prostate-specific antigen and negative prostate biopsies

Cancer Prevention Research

Volumn 2, Issue 4, 2009, Pages 377-384

  Zanardi, Silvia ^a   Puntoni, Matteo ^a,b   Maffezzini, Massimo ^a   Bandelloni, Roberto ^a   Mori, Marco ^a   Argusti, Alessandra ^a   Campodonico, Fabio ^a   Turbino, Laura ^a   Branchi, Daniela ^a   Montironi, Rodolfo ^c   Decensi, Andrea ^a,d  

^a GALLIERA HOSPITAL   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; ESTRADIOL; KI 67 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; ANILIDE; ANTIANDROGEN; NITRILE; TOLUENESULFONIC ACID DERIVATIVE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; BREAST AUGMENTATION; CANCER GRADING; CLINICAL TRIAL; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; ESTRADIOL BLOOD LEVEL; FATIGUE; GYNECOMASTIA; HEART ARRHYTHMIA; HOT FLUSH; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMPOTENCE; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; NOCTURIA; OUTCOME ASSESSMENT; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POLLAKISURIA; PREVALENCE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; SEXUAL DYSFUNCTION; SIDE EFFECT; SINGLE DRUG DOSE; STROKE; SUBDURAL HEMATOMA; SWELLING; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; WEIGHT GAIN; BIOPSY; BLOOD; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG EFFECT; MIDDLE AGED; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANILIDES; BIOPSY; DOSE-RESPONSE RELATIONSHIP, DRUG; GYNECOMASTIA; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NITRILES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; TOSYL COMPOUNDS;

EID: 67549149795     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-08-0205     Document Type: Article

References (33)

1. Kelloff GJ, Lippman SM, Dannenberg AJ, et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer - a plan to move forward. Clin Cancer Res 2006;12:3661-3697
2. Pames HL, Thompson IM, Ford LG. Prevention of hormone-related cancers: prostate cancer. J Clin Oncol 2005;23:368-377 (Pubitemid 46206884)
3. Lippman SM, Goodman PJ, Klein EA, et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst 2005;97:94-102.
4. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-224 (Pubitemid 36859473)
5. Scardino PT. The prevention of prostate cancer - the dilemma continues. N Engl J Med 2003;349:297-299 (Pubitemid 36859482)
6. Logothetis CJ, Schellhammer PF. High-grade prostate cancer and the Prostate Cancer Prevention Trial. Cancer Prev Res 2008;1:151-152
7. Redman MW, Tangen CM, Goodman PJ, Lucia SM, Coltman CA, Jr., Thompson IM. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res 2008;1:174-181
8. McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006;97:247-254
9. Cockshott ID, Cooper KJ, Sweetmore DS, Blacklock NJ, Denis L. The pharmacokinetics of Casodex in prostate cancer patients after single and during multiple dosing. Eur Urol 1990;18 Suppl 3:10-17
10. Simard J, Singh SM, Labrie F. Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameters. Urology 1997;49:580-6; discussion 6-9. (Pubitemid 27161418)
11. Lopez-Corona E, Ohori M, Scardino PT, Reuter VE, Gonen M, Kattan MW. A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session. J Urol 2003;170:1184-8; discussion 8. (Pubitemid 37108108)
12. Okegawa T, Kinjo M, Ohta M, et al. Predictors of prostate cancer on repeat prostatic biopsy in men with serum total prostate-specific antigen between 4.1 and 10 ng/mL. Int J Urol 2003;10:201-206 (Pubitemid 36606369)
13. Stratton MS, Reid ME, Schwartzberg G, et al. Selenium and prevention of prostate cancer in highrisk men: the Negative Biopsy Study. Anticancer Drugs 2003;14:589-594 (Pubitemid 37297258)
14. Andriole G, Bostwick D, Brawley O, et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 2004;172:1314-1317 (Pubitemid 39249705)
15. O'Shaughnessy JA, Kelloff GJ, Gordon GB, et al. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 2002;8:314-346
16. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349:366-381
17. National Cancer Institute-Common Terminology Criteria for Adverse Events, version 3.0, revised June 10, 2003. http://ctep.cancer.gov.
18. Montironi R, Mazzucchelli R, Algaba F, Lopez-Beltran A. Morphological identification of the patterns of prostatic intraepithelial neoplasia and their importance. J Clin Pathol 2000;53:655-665 (Pubitemid 30692403)
19. De Marzo AM, Platz EA, Epstein JI, et al. A Working Group Classification of focal prostate atrophy lesions. Am J Surg Pathol 2006;30:1281-1291 (Pubitemid 44454708)
20. Decensi A, Robertson C, Viale G, et al. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 2003;95:779-790 (Pubitemid 36798424)
21. Benjamini Y, Hochberg Y. Controlling the false discovery rates: a practical and powerful approach to multiple testing. J Roy Stat Soc B 1995;35:289-300.
22. Bono AV, Mazzucchelli R, Ferrari I, et al. Bicalutamide 50 mg monotherapy in patients with isolated high-grade PIN: findings in repeat biopsies at 6 months. J Clin Pathol 2007;60:443-446 (Pubitemid 46596574)
23. Scattoni V, Montironi R, Mazzucchelli R, et al. Pathological changes of high-grade prostatic intraepithelial neoplasia and prostate cancer after monotherapy with bicalutamide 150 mg. BJU Int 2006;98:54-58 (Pubitemid 43885504)
24. Bubendorf L, Tapia C, Gasser TC, et al. Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer. Hum Pathol 1998;29:949-954 (Pubitemid 28422042)
25. Pollack A, DeSilvio M, Khor LY, et al. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. J Clin Oncol 2004;22:2133-2140 (Pubitemid 41095146)
26. Agus DB, Cordon-Cardo C, Fox W, et al. Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst 1999;91:1869-1876
27. Singh RP, Sharma G, Dhanalakshmi S, Agarwal C, Agarwal R. Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis. Cancer Epidemiol Biomarkers Prev 2003;12:933-939 (Pubitemid 37151532)
28. Ananthanarayanan V, Deaton RJ, Yang XJ, Pins MR, Gann PH. Alteration of proliferation and apoptotic markers in normal and premalignant tissue associated with prostate cancer. BMC Cancer 2006;6:73. (Pubitemid 46277068)
29. Bostwick DG, Qian J. High-grade prostatic intraepithelial neoplasia. Mod Pathol 2004;17:360-379
30. Verhelst J, Denis L, Van Vliet P, et al. Endocrine profiles during administration of the new nonsteroidal anti-androgen Casodex in prostate cancer. Clin Endocrinol (Oxf) 1994;41:525-530 (Pubitemid 24301287)
31. Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol 2003;21:383-391
32. Thompson IM, Pauler Ankerst D, Chi C, et al. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. J Clin Oncol 2007;25:3076-3081 (Pubitemid 47218054)
33. Zhigang Z, Wenlu S. Flutamide reduced prostate cancer development and prostate stem cell antigen mRNA expression in high grade prostatic intraepithelial neoplasia. Int J Cancer 2008;122:864-870